Immune escape by Epstein-Barr virus associated malignancies

UMMS Affiliation

Department of Quantitative Health Sciences; Department of Pediatrics

Publication Date


Document Type



Antigens, Viral; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cancer Vaccines; Epstein-Barr Virus Infections; HIV Infections; Herpesvirus 4, Human; Humans; Malaria, Falciparum; Neoplasms; Tumor Escape; Virus Activation; Virus Latency


Biostatistics | Epidemiology | Health Services Research | Immunology and Infectious Disease | Pediatrics


Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.

DOI of Published Version



Semin Cancer Biol. 2008 Dec;18(6):381-7. Epub 2008 Oct 19. Link to article on publisher's site

Journal/Book/Conference Title

Seminars in cancer biology

PubMed ID


Related Resources

Link to Article in PubMed